Pancreatic Cancer Research

ResearcherFirst Hospital of China Medical UniversityActive in the last 2 years

Ming Dong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2685-1420; OpenAlex author ID A5100618888. Sources: OpenAlex.

Their work

Papers
31 (first author 13, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 6 papers · 2023: none · 2024: 2 papers

Papers 31

  1. MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progression. Last author DOI 10.1186/s12935-024-03444-9↗
  2. Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2. Last author DOI 10.3892/or.2024.8752↗
  3. Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer. Last author DOI 10.1038/s41419-022-04609-y↗
  4. Correction: Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. First author DOI 10.18632/oncotarget.28157↗
  5. Calreticulin promotes EMT in pancreatic cancer by enhancing endoplasmic reticulum stress-induced autophagy Co-author DOI 10.21203/rs.3.rs-1963841/v1↗
  6. [Corrigendum] Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. First author DOI 10.3892/or.2022.8395↗
  7. Down-regulation of MSMO1 promotes the development and progression of pancreatic cancer. Last author DOI 10.7150/jca.73112↗
  8. ATP11A promotes EMT by regulating Numb PRR L in pancreatic cancer cells. Last author DOI 10.7717/peerj.13172↗
  9. MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. Last author DOI 10.3389/fonc.2021.616481↗
  10. Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1 pathway. Last author DOI 10.1111/jcmm.15676↗
  11. Correction to: Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. Last author DOI 10.1186/s13046-020-01663-2↗
  12. Calreticulin promotes EMT in pancreatic cancer via mediating Ca2+ dependent acute and chronic endoplasmic reticulum stress. Last author DOI 10.1186/s13046-020-01702-y↗
  13. Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. Last author DOI 10.1186/s13046-020-1521-4↗
  14. C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway. First author DOI 10.1007/s11010-018-3455-0↗
  15. Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53. Last author DOI 10.1111/febs.14778↗
  16. Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells. Co-author DOI 10.3892/mmr.2018.9331↗
  17. Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer. First author DOI 10.3892/or.2018.6216↗
  18. Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Co-author DOI 10.1038/cddis.2017.547↗
  19. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. First author DOI 10.1096/fj.201601240r↗
  20. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. First author DOI 10.18632/oncotarget.8736↗
  21. Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer. First author DOI 10.1007/s12253-015-9935-6↗
  22. Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC. Last author DOI 10.3892/or.2016.4592↗
  23. GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK. First author DOI 10.1007/s11010-014-2204-2↗
  24. Gli1 promotes transforming growth factor-beta1- and epidermal growth factor-induced epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1016/j.surg.2015.03.016↗
  25. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. First author DOI 10.1111/his.12663↗
  26. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. Co-author DOI 10.1002/jcp.24519↗
  27. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer. First author DOI 10.1111/his.12273↗
  28. [Expression and significance of leukemia inhibitory factor in human pancreatic cancer]. Last author PMID 24721346↗
  29. Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer. First author DOI 10.1002/jso.23282↗
  30. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. First author DOI 10.1007/s00441-013-1679-6↗
  31. [Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer]. First author PMID 23327700↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weiwei Sheng · 27 shared papers, 2012–2022 · strength 2.68
  2. Jianping Zhou · 14 shared papers, 2012–2022 · strength 1.11
  3. Jian Hua Sun · 6 shared papers, 2020–2024 · strength 0.99
  4. Qi Dong · 9 shared papers, 2013–2022 · strength 0.80
  5. Rongxian Cao · 6 shared papers, 2020–2022 · strength 0.80
  6. Guosen Wang · 6 shared papers, 2017–2020 · strength 0.62
  7. Chao Jia · 4 shared papers, 2020 · strength 0.43
  8. Banghua Zhong · 2 shared papers, 2022–2024 · strength 0.43
  9. Qingfeng Liu · 5 shared papers, 2013–2022 · strength 0.42
  10. Longping Huang · 2 shared papers, 2016–2024 · strength 0.34
  11. Yuji Li · 4 shared papers, 2012–2017 · strength 0.27
  12. Feng Li · 4 shared papers, 2013–2015 · strength 0.19
  13. Lin Chen · 1 shared paper, 2022 · strength 0.19
  14. Song He · 1 shared paper, 2022 · strength 0.19
  15. Wei Gao · 1 shared paper, 2022 · strength 0.19
  16. Song He · 2 shared papers, 2017–2018 · strength 0.17
  17. Hong-jia Wu · 1 shared paper, 2022 · strength 0.15
  18. Matthias Ilmer · 1 shared paper, 2022 · strength 0.15
  19. Yunwei Li · 2 shared papers, 2016–2017 · strength 0.14
  20. Kewei Wang · 2 shared papers, 2015–2017 · strength 0.13
  21. Xin Li · 1 shared paper, 2019 · strength 0.11
  22. Lei Zhou · 1 shared paper, 2020 · strength 0.11
  23. Qingfeng Liu · 2 shared papers, 2014–2015 · strength 0.10
  24. Wei Gao · 1 shared paper, 2018 · strength 0.10
  25. J. P. Zhou · 1 shared paper, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.